Chai Discovery, an artificial intelligence-focused drug development company, has just closed a massive $400 million funding round that values the biotech start-up at $3.8 billion—a striking vote of confidence in using machine learning to solve one of healthcare's toughest puzzles.

The funding surge reflects a broader shift in how the pharmaceutical industry approaches drug discovery. By leveraging AI to identify promising compounds and predict their effectiveness, companies like Chai are potentially cutting years off the traditional development timeline, which can stretch a decade or more. This isn't just good news for investors; it could mean faster access to new treatments for patients who need them. Read the full story →

Today's takeaway: When artificial intelligence meets medicine, the results can be transformative—and investors are betting billions that AI-powered drug discovery is the future.